A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Ixazomib (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Alliance
- 17 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2019.
- 20 Jun 2017 Status changed from recruiting to suspended because DSMB recommendation to revise study design
- 04 Oct 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2017.